{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:56:11Z","timestamp":1793256971940,"version":"4.5.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Around 0.75 million babies worldwide suffer from moderate or severe hypoxic-ischemic encephalopathy (HIE) each year resulting in around 400,000 babies with neurodevelopmental impairment. In 2010, neonatal HIE was associated with 2.4% of the total Global Burden of Disease. Therapeutic hypothermia (TH), a treatment that is now standard of care in high-income countries, provides proof of concept that strategies that aim to improve neurodevelopment are not only possible but can also be implemented to clinical practice. While TH is beneficial, neonates with moderate or severe HIE treated with TH still experience devastating complications: 48% (range: 44\u201353) combined death or moderate\/severe disability. There is a concern that TH may not be effective in low- and middle-income countries. Therapies that further improve outcomes are desperately needed, and in high-income countries, they must be tested in conjunction with TH. We have in this review focussed on pharmacological treatment options (e.g. erythropoietin, allopurinol, melatonin, cannabidiol, exendin-4\/exenatide). Erythropoietin and allopurinol show promise and are progressing towards the clinic with ongoing definitive phase 3 randomised placebo-controlled trials. However, there remain global challenges for the next decade.\u00a0<\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    : There is a need for more optimal animal models, greater industry support\/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials to avoid exposure to harmful medications or abandoning putative treatments.\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is Known:<\/jats:bold>\n                              <jats:italic>\u2022 Therapeutic hypothermia is beneficial in neonatal hypoxic-ischemic encephalopathy.<\/jats:italic>\n                              <jats:italic>\u2022 Neonates with moderate or severe hypoxic-ischemic encephalopathy treated with therapeutic hypothermia still experience severe sequelae.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>What is New:<\/jats:bold>\n                              <jats:italic>\u2022 Erythropoietin, allopurinol, melatonin, cannabidiol, and exendin-4\/exenatide show promise in conjunction with therapeutic hypothermia.<\/jats:italic>\n                              <jats:italic>\u2022 There is a need for more optimal animal models, greater industry support\/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-021-04320-8","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T18:02:34Z","timestamp":1637776954000},"page":"875-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy"],"prefix":"10.1007","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5314-7626","authenticated-orcid":false,"given":"Suresh","family":"Victor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eridan","family":"Rocha-Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahad","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"4320_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.earlhumdev.2010.05.010","volume":"86","author":"JJ Kurinczuk","year":"2010","unstructured":"Kurinczuk JJ, White-Koning M, Badawi N (2010) Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev 86:329\u2013338. https:\/\/doi.org\/10.1016\/j.earlhumdev.2010.05.010","journal-title":"Early Hum Dev"},{"key":"4320_CR2","doi-asserted-by":"publisher","first-page":"F301","DOI":"10.1136\/archdischild-2017-313707","volume":"103","author":"C Gale","year":"2018","unstructured":"Gale C, Statnikov Y, Jawad S, Uthaya SN, Modi N (2018) Neonatal brain injuries in England: population-based incidence derived from routinely recorded clinical data held in the National Neonatal Research Database. Arch Dis Child Fetal Neonatal Ed 103:F301\u2013F306. https:\/\/doi.org\/10.1136\/archdischild-2017-313707","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"4320_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/pr.2013.206","volume":"74","author":"ACC Lee","year":"2013","unstructured":"Lee ACC, Kozuki N, Blencowe H, Vos T et al (2013) Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pediatr Res 74:50\u201372. https:\/\/doi.org\/10.1038\/pr.2013.206","journal-title":"Pediatr Res"},{"key":"4320_CR4","doi-asserted-by":"publisher","first-page":"C363","DOI":"10.1136\/bmj.c363","volume":"340","author":"AD Edwards","year":"2010","unstructured":"Edwards AD, Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, Levene M, Strohm B, Thoresen M, Whitelaw A, Azzopardi D (2010) Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ (Online) 340:C363. https:\/\/doi.org\/10.1136\/bmj.c363","journal-title":"BMJ (Online)"},{"key":"4320_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/ARCHPEDIATRICS.2011.1772","volume":"166","author":"MA Tagin","year":"2012","unstructured":"Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA (2012) Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc Med 166:558\u2013566. https:\/\/doi.org\/10.1001\/ARCHPEDIATRICS.2011.1772","journal-title":"Arch Pediatr Adolesc Med"},{"key":"4320_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/bmjpo-2017-000245","volume":"2","author":"V Oliveira","year":"2018","unstructured":"Oliveira V, Raman Kumutha J, Somanna J et al (2018) Hypothermia for encephalopathy in low-income and middle-income countries: feasibility of whole-body cooling using a low-cost servo-controlled device on behalf of HELIX consortium. BMJ Paediatr Open 2:245. https:\/\/doi.org\/10.1136\/bmjpo-2017-000245","journal-title":"BMJ Paediatr Open"},{"key":"4320_CR7","doi-asserted-by":"publisher","first-page":"e1273","DOI":"10.1016\/S2214-109X(21)00264-3","volume":"9","author":"S Thayyil","year":"2021","unstructured":"Thayyil S, Pant S, Montaldo P et al (2021) Hypothermia for moderate or severe neonatal encephalopathy in low-income and middle-income countries (HELIX): a randomised controlled trial in India, Sri Lanka, and Bangladesh. Lancet Glob Health 9:e1273\u2013e1285. https:\/\/doi.org\/10.1016\/S2214-109X(21)00264-3","journal-title":"Lancet Glob Health"},{"key":"4320_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/jnen\/60.4.386","volume":"60","author":"A Nagai","year":"2001","unstructured":"Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60:386\u2013392. https:\/\/doi.org\/10.1093\/jnen\/60.4.386","journal-title":"J Neuropathol Exp Neurol"},{"key":"4320_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1432-1033.1996.0494U.x","volume":"239","author":"R Yamaji","year":"1996","unstructured":"Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, Nakano Y (1996) Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239:494\u2013500. https:\/\/doi.org\/10.1111\/j.1432-1033.1996.0494U.x","journal-title":"Eur J Biochem"},{"key":"4320_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1242\/dev.129.2.505","volume":"129","author":"X Yu","year":"2002","unstructured":"Yu X, Shacka JJ, Eells JB, Suarez-Quian C et al (2002) Erythropoietin receptor signalling is required for normal brain development. Development 129:505\u2013515. https:\/\/doi.org\/10.1242\/dev.129.2.505","journal-title":"Development"},{"key":"4320_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s100249900103","volume":"2","author":"SE Juul","year":"1999","unstructured":"Juul SE, Yachnis AT, Rojiani AM, Christensen RD (1999) Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 2:148\u2013158. https:\/\/doi.org\/10.1007\/s100249900103","journal-title":"Pediatr Dev Pathol"},{"key":"4320_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1161\/STROKEAHA.111.000104","volume":"44","author":"FF Gonzalez","year":"2013","unstructured":"Gonzalez FF, Larpthaveesarp A, McQuillen P, Derugin N, Wendland M, Spadafora R, Ferriero DM (2013) Erythropoietin increases neurogenesis and oligodendrogliosis of subventricular zone precursor cells after neonatal stroke. Stroke 44:753\u2013758. https:\/\/doi.org\/10.1161\/STROKEAHA.111.000104","journal-title":"Stroke"},{"key":"4320_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fncel.2013.00235","volume":"7","author":"N Kaneko","year":"2013","unstructured":"Kaneko N, Kako E, Sawamoto K (2013) Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives. Front Cell Neurosci 7:235. https:\/\/doi.org\/10.3389\/fncel.2013.00235","journal-title":"Front Cell Neurosci"},{"key":"4320_CR14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3171\/2009.9.JNS09844","volume":"113","author":"Y Xiong","year":"2010","unstructured":"Xiong Y, Mahmood A, Meng Y, Zhang Y, Qu C, Schallert T, Chopp M (2010) Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improves functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose. J Neurosurg 113:598\u2013608. https:\/\/doi.org\/10.3171\/2009.9.JNS09844","journal-title":"J Neurosurg"},{"key":"4320_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1440-1827.2005.01877.x","volume":"55","author":"E Ikeda","year":"2005","unstructured":"Ikeda E (2005) Cellular response to tissue hypoxia and its involvement in disease progression. Pathol Int 55:603\u2013610. https:\/\/doi.org\/10.1111\/j.1440-1827.2005.01877.x","journal-title":"Pathol Int"},{"key":"4320_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/sj.jcbfm.9600370","volume":"27","author":"P Villa","year":"2007","unstructured":"Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, Brines M, Leist M, Ghezzi P, Torup L (2007) Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 27:552\u2013563. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600370","journal-title":"J Cereb Blood Flow Metab"},{"key":"4320_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1203\/PDR.0b013e31819d90c8","volume":"65","author":"SE Juul","year":"2009","unstructured":"Juul SE, Beyer RP, Bammler TK, Mcpherson RJ, Wilkerson J, Farin FM (2009) Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus. Pediatr Res 65:485\u2013492. https:\/\/doi.org\/10.1203\/PDR.0b013e31819d90c8","journal-title":"Pediatr Res"},{"key":"4320_CR18","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1523\/JNEUROSCI.5380-05.2006","volume":"26","author":"L Wang","year":"2006","unstructured":"Wang L, Zhang ZG, Zhang RL, Gregg SR, Hozeska-Solgot A, LeTourneau Y, Wang Y, Chopp M (2006) Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci 26:5996\u20136003. https:\/\/doi.org\/10.1523\/JNEUROSCI.5380-05.2006","journal-title":"J Neurosci"},{"key":"4320_CR19","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1161\/STROKEAHA.107.483008","volume":"38","author":"M Iwai","year":"2007","unstructured":"Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J (2007) Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia\/ischemia in rats. Stroke 38:2795\u20132803. https:\/\/doi.org\/10.1161\/STROKEAHA.107.483008","journal-title":"Stroke"},{"key":"4320_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000110348","volume":"30","author":"SE Juul","year":"2008","unstructured":"Juul SE, McPherson RJ, Bammler TK, Wilkerson J, Beyer RP, Farin FM (2008) Recombinant erythropoietin is neuroprotective in a novel mouse oxidative injury model. Dev Neurosci 30:231\u2013242. https:\/\/doi.org\/10.1159\/000110348","journal-title":"Dev Neurosci"},{"key":"4320_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1203\/PDR.0b013e3181fcbef3","volume":"69","author":"X Fan","year":"2011","unstructured":"Fan X, Heijnen CJ, van der Kooij MA, Groenendaal F, van Bel F (2011) Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia-ischemia in neonatal mice. Pediatr Res 69:56\u201361. https:\/\/doi.org\/10.1203\/PDR.0b013e3181fcbef3","journal-title":"Pediatr Res"},{"key":"4320_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.nbd.2016.04.006","volume":"93","author":"A Larpthaveesarp","year":"2016","unstructured":"Larpthaveesarp A, Georgevits M, Ferriero DM, Gonzalez FF (2016) Delayed erythropoietin therapy improves histological and behavioral outcomes after transient neonatal stroke. Neurobiol Dis 93:57\u201363. https:\/\/doi.org\/10.1016\/j.nbd.2016.04.006","journal-title":"Neurobiol Dis"},{"key":"4320_CR23","doi-asserted-by":"publisher","unstructured":"van de Looij Y, Chatagner A, Quairiaux C, Gruetter R, H\u00fcppi PS, Sizonenko S (2014) Multi-modal assessment of long-term erythropoietin treatment after neonatal hypoxic-ischemic injury in rat brain. PLoS One 9:e95643. https:\/\/doi.org\/10.1371\/journal.pone.0095643","DOI":"10.1371\/journal.pone.0095643"},{"key":"4320_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000355460","volume":"35","author":"CM Traudt","year":"2013","unstructured":"Traudt CM, Mcpherson RJ, Bauer LA, Richards TL, Burbacher TM, Mcadams RM, Juul SE (2013) Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia. Dev Neurosci 35:491\u2013503. https:\/\/doi.org\/10.1159\/000355460","journal-title":"Dev Neurosci"},{"key":"4320_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000470903","volume":"39","author":"RM McAdams","year":"2017","unstructured":"McAdams RM, Fleiss B, Traudt C, Schwendimann L, Snyder JM, Haynes RL, Natarajan N, Gressens P, Juul SE (2017) Long-term neuropathological changes associated with cerebral palsy in a nonhuman primate model of hypoxic-ischemic encephalopathy. Dev Neurosci 39:124\u2013140. https:\/\/doi.org\/10.1159\/000470903","journal-title":"Dev Neurosci"},{"key":"4320_CR26","doi-asserted-by":"publisher","unstructured":"Pang R, Avdic-Belltheus A, Meehan C et al (2021) Melatonin and\/or erythropoietin combined with hypothermia in a piglet model of perinatal asphyxia. Brain Commun 3:fcaa211. https:\/\/doi.org\/10.1093\/braincomms\/fcaa211","DOI":"10.1093\/braincomms\/fcaa211"},{"key":"4320_CR27","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3390\/ijms21041487","volume":"21","author":"DE Oorschot","year":"2020","unstructured":"Oorschot DE, Sizemore RJ, Amer AR (2020) Treatment of neonatal hypoxic-ischemic encephalopathy with erythropoietin alone, and erythropoietin combined with hypothermia: history, current status, and future research. Int J Mol Sci 21:1487. https:\/\/doi.org\/10.3390\/ijms21041487","journal-title":"Int J Mol Sci"},{"key":"4320_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1542\/peds.2012-0498","volume":"130","author":"YW Wu","year":"2012","unstructured":"Wu YW, Bauer LA, Ballard RA, Ferriero DM et al (2012) Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 130:683\u2013691. https:\/\/doi.org\/10.1542\/peds.2012-0498","journal-title":"Pediatrics"},{"key":"4320_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/pr.2017.15","volume":"81","author":"A Frymoyer","year":"2017","unstructured":"Frymoyer A, Juul SE, Massaro AN, Bammler TK, Wu YW (2017) High-dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. Pediatr Res 81:865\u2013872. https:\/\/doi.org\/10.1038\/pr.2017.15","journal-title":"Pediatr Res"},{"key":"4320_CR30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/jp.2017.17","volume":"37","author":"RR Malla","year":"2017","unstructured":"Malla RR, Asimi R, Teli MA, Shaheen F, Bhat MA (2017) Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. J Perinatol 37:596\u2013601. https:\/\/doi.org\/10.1038\/jp.2017.17","journal-title":"J Perinatol"},{"key":"4320_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/pr.2015.101","volume":"78","author":"MC Baserga","year":"2015","unstructured":"Baserga MC, Beachy JC, Roberts JK et al (2015) Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatr Res 78:315\u2013322. https:\/\/doi.org\/10.1038\/pr.2015.101","journal-title":"Pediatr Res"},{"key":"4320_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.pediatrneurol.2014.08.010","volume":"51","author":"EE Rogers","year":"2014","unstructured":"Rogers EE, Bonifacio SL, Glass HC et al (2014) Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatr Neurol 51:657\u2013662. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2014.08.010","journal-title":"Pediatr Neurol"},{"key":"4320_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12887-018-1389-z","volume":"19","author":"M Nonomura","year":"2019","unstructured":"Nonomura M, Harada S, Asada Y, Matsumura H, Iwami H, Tanaka Y, Ichiba H (2019) Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy: an open-label pilot study to assess the safety and feasibility. BMC Pediatr 19:13. https:\/\/doi.org\/10.1186\/s12887-018-1389-z","journal-title":"BMC Pediatr"},{"key":"4320_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jpeds.2017.03.053","volume":"186","author":"SB Mulkey","year":"2017","unstructured":"Mulkey SB, Ramakrishnaiah RH, McKinstry RC et al (2017) Erythropoietin and brain magnetic resonance imaging findings in hypoxic-ischemic encephalopathy: volume of acute brain injury and 1-year neurodevelopmental outcome. J Pediatr 186:196\u2013199. https:\/\/doi.org\/10.1016\/j.jpeds.2017.03.053","journal-title":"J Pediatr"},{"key":"4320_CR35","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3109\/14767058.2013.855894","volume":"27","author":"MS El Shimi","year":"2014","unstructured":"El Shimi MS, Awad HA, Hassanein SMA, Gad GI, Imam SS, Shaaban HA, El Maraghy MO (2014) Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings. J Matern Fetal Neonatal Med 27:1295\u20131300. https:\/\/doi.org\/10.3109\/14767058.2013.855894","journal-title":"J Matern Fetal Neonatal Med"},{"key":"4320_CR36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/ped.12121","volume":"55","author":"A Avasiloaiei","year":"2013","unstructured":"Avasiloaiei A, Dimitriu C, Moscalu M, Paduraru L, Stamatin M (2013) High-dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatr Int 55:589\u2013593. https:\/\/doi.org\/10.1111\/ped.12121","journal-title":"Pediatr Int"},{"key":"4320_CR37","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1542\/peds.2009-2268","volume":"125","author":"H Elmahdy","year":"2010","unstructured":"Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H (2010) Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 125:e1135\u2013e1142. https:\/\/doi.org\/10.1542\/peds.2009-2268","journal-title":"Pediatrics"},{"key":"4320_CR38","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1542\/peds.2008-3553","volume":"124","author":"C Zhu","year":"2009","unstructured":"Zhu C, Kang W, Xu F et al (2009) Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 124:e218\u2013e226. https:\/\/doi.org\/10.1542\/peds.2008-3553","journal-title":"Pediatrics"},{"key":"4320_CR39","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0191","volume":"137","author":"YW Wu","year":"2016","unstructured":"Wu YW, Mathur AM, Chang T et al (2016) High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. Pediatrics 137:e20160191. https:\/\/doi.org\/10.1542\/peds.2016-0191","journal-title":"Pediatrics"},{"key":"4320_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000486820","volume":"113","author":"SE Juul","year":"2018","unstructured":"Juul SE, Comstock BA, Heagerty PJ, Mayock DE, Goodman AM, Hauge S, Gonzalez F, Wu YW (2018) High-dose erythropoietin for asphyxia and encephalopathy (HEAL): a randomized controlled trial-background, aims, and study protocol. Neonatology 113:331\u2013338. https:\/\/doi.org\/10.1159\/000486820","journal-title":"Neonatology"},{"key":"4320_CR41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2174\/1570159X14666161228122","volume":"15","author":"S Tordjman","year":"2017","unstructured":"Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, Fougerou C (2017) Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol 15:434\u2013443. https:\/\/doi.org\/10.2174\/1570159X14666161228122","journal-title":"Curr Neuropharmacol"},{"key":"4320_CR42","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2174\/1381612822666151214104624","volume":"22","author":"L Sagrillo-Fagundes","year":"2016","unstructured":"Sagrillo-Fagundes L, Maria Assuncao Salustiano E, Wong Yen P, Soliman A, Vaillancourt C (2016) Melatonin in pregnancy: effects on brain development and CNS programming disorders. Curr Pharm Des 22:978\u2013986. https:\/\/doi.org\/10.2174\/1381612822666151214104624","journal-title":"Curr Pharm Des"},{"key":"4320_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0006-8993(97)00335-1","volume":"761","author":"JE Drew","year":"1997","unstructured":"Drew JE, Williams LM, Hannah LT, Barrett P, Abramovich DR, Morgan PJ (1997) Identification and characterisation of 2-[125I]iodomelatonin binding and Mel1a melatonin receptor expression in the human fetal leptomeninges. Brain Res 761:87\u201392. https:\/\/doi.org\/10.1016\/s0006-8993(97)00335-1","journal-title":"Brain Res"},{"key":"4320_CR44","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1034\/j.1600-079X.2002.02921.x","volume":"33","author":"L Thomas","year":"2002","unstructured":"Thomas L, Purvis C, Drew JE, Abramovich R, Williams LM (2002) Melatonin receptors in human fetal brain: 2-[125I]iodomelatonin binding and MT1 gene expression. J Pineal Res 33:218\u2013224. https:\/\/doi.org\/10.1034\/j.1600-079X.2002.02921.x","journal-title":"J Pineal Res"},{"key":"4320_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1034\/j.1600-079x.2001.280204.x","volume":"28","author":"Y Okatani","year":"2000","unstructured":"Okatani Y, Wakatsuki A, Kaneda C (2000) Melatonin increases activities of glutathione peroxidase and superoxide dismutase in fetal rat brain. J Pineal Res 28:89\u201396. https:\/\/doi.org\/10.1034\/j.1600-079x.2001.280204.x","journal-title":"J Pineal Res"},{"key":"4320_CR46","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/biom10091211","volume":"10","author":"DM Chitimus","year":"2020","unstructured":"Chitimus DM, Popescu MR, Voiculescu SE, Panaitescu AM, Pavel B, Zagrean L, Zagrean A-M (2020) Melatonin\u2019s impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease. Biomolecules 10:1211\u20131239. https:\/\/doi.org\/10.3390\/biom10091211","journal-title":"Biomolecules"},{"key":"4320_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1034\/j.1600-079X.2001.310211.x","volume":"31","author":"A Wakatsuki","year":"2001","unstructured":"Wakatsuki A, Okatani Y, Shinohara K, Ikenoue N, Fukaya T (2001) Melatonin protects against ischemia\/reperfusion-induced oxidative damage to mitochondria in fetal rat brain. J Pineal Res 31:167\u2013172. https:\/\/doi.org\/10.1034\/j.1600-079X.2001.310211.x","journal-title":"J Pineal Res"},{"key":"4320_CR48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/brain\/aws285","volume":"136","author":"NJ Robertson","year":"2013","unstructured":"Robertson NJ, Faulkner S, Fleiss B et al (2013) Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain 136:90\u2013105. https:\/\/doi.org\/10.1093\/brain\/aws285","journal-title":"Brain"},{"key":"4320_CR49","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1038\/s41598-020-60858-x","volume":"10","author":"NJ Robertson","year":"2020","unstructured":"Robertson NJ, Lingam I, Meehan C et al (2020) High-dose melatonin and ethanol excipient combined with therapeutic hypothermia in a newborn piglet asphyxia model. Sci Rep 10:3898. https:\/\/doi.org\/10.1038\/s41598-020-60858-x","journal-title":"Sci Rep"},{"key":"4320_CR50","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.nbd.2018.10.004","volume":"121","author":"NJ Robertson","year":"2019","unstructured":"Robertson NJ, Martinello K, Lingam I et al (2019) Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: a translational study. Neurobiol Dis 121:240\u2013251. https:\/\/doi.org\/10.1016\/j.nbd.2018.10.004","journal-title":"Neurobiol Dis"},{"key":"4320_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12479","volume":"64","author":"JDS Aridas","year":"2018","unstructured":"Aridas JDS, Yawno T, Sutherland AE et al (2018) Systemic and transdermal melatonin administration prevents neuropathology in response to perinatal asphyxia in newborn lambs. J Pineal Res 64:e12479. https:\/\/doi.org\/10.1111\/jpi.12479","journal-title":"J Pineal Res"},{"key":"4320_CR52","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.3390\/ijms22115481","volume":"22","author":"R Pang","year":"2021","unstructured":"Pang R, Advic-Belltheus A, Meehan C, Fullen DJ, Golay X, Robertson NJ (2021) Melatonin for neonatal encephalopathy: from bench to bedside. Int J Mol Sci 22:5481. https:\/\/doi.org\/10.3390\/ijms22115481","journal-title":"Int J Mol Sci"},{"key":"4320_CR53","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaac.2017.09.414","volume":"56","author":"P Gringras","year":"2017","unstructured":"Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL (2017) Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Aca Child Adolesc Psychiatry 56:948-957.e4. https:\/\/doi.org\/10.1016\/j.jaac.2017.09.414","journal-title":"J Am Aca Child Adolesc Psychiatry"},{"key":"4320_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004141","volume":"3","author":"NO Alers","year":"2013","unstructured":"Alers NO, Jenkin G, Miller SL, Wallace EM (2013) Antenatal melatonin as an antioxidant in human pregnancies complicated by fetal growth restriction - a phase I pilot clinical trial: study protocol. BMJ Open 3:e004141. https:\/\/doi.org\/10.1136\/bmjopen-2013-004141","journal-title":"BMJ Open"},{"key":"4320_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003788","volume":"3","author":"SR Hobson","year":"2013","unstructured":"Hobson SR, Lim R, Gardiner EE, Alers NO, Wallace EM (2013) Phase I pilot clinical trial of antenatal maternally administered melatonin to decrease the level of oxidative stress in human pregnancies affected by pre-eclampsia (PAMPR): study protocol. BMJ Open 3:e003788. https:\/\/doi.org\/10.1136\/bmjopen-2013-003788","journal-title":"BMJ Open"},{"key":"4320_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12508","volume":"65","author":"SR Hobson","year":"2018","unstructured":"Hobson SR, Gurusinghe S, Lim R, Alers NO, Miller SL, Kingdom JC, Wallace EM (2018) Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia. J Pineal Res 65:e12508. https:\/\/doi.org\/10.1111\/jpi.12508","journal-title":"J Pineal Res"},{"key":"4320_CR57","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.3390\/molecules22122115","volume":"22","author":"S Carloni","year":"2017","unstructured":"Carloni S, Proietti F, Rocchi M, Longini M, Marseglia L, D\u2019Angelo G, Balduini W, Gitto E, Buonocore G (2017) Melatonin pharmacokinetics following oral administration in preterm neonates. Molecules 22:2115\u20132127. https:\/\/doi.org\/10.3390\/molecules22122115","journal-title":"Molecules"},{"key":"4320_CR58","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/jp.2014.186","volume":"35","author":"H Aly","year":"2015","unstructured":"Aly H, Elmahdy H, El-Dib M, Rowisha M, Awny M, El-Gohary T, Elbatch M, Hamisa M, El-Mashad AR (2015) Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study. J Perinatol 35:186\u2013191. https:\/\/doi.org\/10.1038\/jp.2014.186","journal-title":"J Perinatol"},{"key":"4320_CR59","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3233\/NPM-181830","volume":"12","author":"MS El Farargy","year":"2020","unstructured":"El Farargy MS, Soliman NA (2020) A randomized controlled trial on the use of magnesium sulfate and melatonin in neonatal hypoxic ischemic encephalopathy. J Neonatal Perinatal Med 12:379\u2013384. https:\/\/doi.org\/10.3233\/NPM-181830","journal-title":"J Neonatal Perinatal Med"},{"key":"4320_CR60","first-page":"1233","volume":"68","author":"QM Ahmad","year":"2018","unstructured":"Ahmad QM, Chishti AL, Waseem N (2018) Role of melatonin in management of hypoxic ischaemic encephalopathy in newborns: a randomized control trial. J Pak Med Assoc 68:1233\u20131237","journal-title":"J Pak Med Assoc"},{"key":"4320_CR61","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1034\/j.1600-079X.2001.310409.x","volume":"31","author":"F Fulia","year":"2001","unstructured":"Fulia F, Gitto E, Cuzzocrea S, Reiter RJ, Dugo L, Gitto P, Barberi S, Cordaro S, Barberi I (2001) Increased levels of malondialdehyde and nitrite\/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res 31:343\u2013349. https:\/\/doi.org\/10.1034\/j.1600-079X.2001.310409.x","journal-title":"J Pineal Res"},{"key":"4320_CR62","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/PCC.0000000000002346","volume":"21","author":"A Jerez-Calero","year":"2020","unstructured":"Jerez-Calero A, Salvatierra-Cuenca MT, Benitez-Feliponi \u00c1, Fern\u00e1ndez-Mar\u00edn CE, Narbona-L\u00f3pez E, Uberos-Fern\u00e1ndez J, Mun\u00f5z-Hoyos A (2020) Hypothermia plus melatonin in asphyctic newborns: a randomized-controlled pilot study. Pediatr Crit Care Med 21:647\u2013655. https:\/\/doi.org\/10.1097\/PCC.0000000000002346","journal-title":"Pediatr Crit Care Med"},{"key":"4320_CR63","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ijms19030833","volume":"19","author":"S Zou","year":"2018","unstructured":"Zou S, Kumar U (2018) Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci 19:833. https:\/\/doi.org\/10.3390\/ijms19030833","journal-title":"Int J Mol Sci"},{"key":"4320_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.584533","volume":"11","author":"J Mart\u00ednez-Orgado","year":"2021","unstructured":"Mart\u00ednez-Orgado J, Villa M, del Pozo A (2021) Cannabidiol for the treatment of neonatal hypoxic-ischemic brain injury. Front Pharmacol 11:584533. https:\/\/doi.org\/10.3389\/fphar.2020.584533","journal-title":"Front Pharmacol"},{"key":"4320_CR65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","volume":"112","author":"AC Campos","year":"2016","unstructured":"Campos AC, Foga\u00e7a MV, Sonego AB, Guimar\u00e3es FS (2016) Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res 112:119\u2013127. https:\/\/doi.org\/10.1016\/j.phrs.2016.01.033","journal-title":"Pharmacol Res"},{"key":"4320_CR66","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","volume":"71","author":"MR Pazos","year":"2013","unstructured":"Pazos MR, Mohammed N, Lafuente H et al (2013) Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT1A and CB2 receptors. Neuropharmacology 71:282\u2013291. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.03.027","journal-title":"Neuropharmacology"},{"key":"4320_CR67","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.nbd.2009.10.023","volume":"37","author":"A Castillo","year":"2010","unstructured":"Castillo A, Tol\u00f3n MR, Fern\u00e1ndez-Ruiz J, Romero J, Martinez-Orgado J (2010) The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiol Dis 37:434\u2013440. https:\/\/doi.org\/10.1016\/j.nbd.2009.10.023","journal-title":"Neurobiol Dis"},{"key":"4320_CR68","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neuropharm.2019.02.004","volume":"152","author":"R Franco","year":"2019","unstructured":"Franco R, Villa M, Morales P, Reyes-Resina I, Guti\u00e9rrez-Rodr\u00edguez A, Jim\u00e9nez J, Jagerovic N, Mart\u00ednez-Orgado J, Navarro G (2019) Increased expression of cannabinoid CB2 and serotonin 5-HT1A heteroreceptor complexes in a model of newborn hypoxic-ischemic brain damage. Neuropharmacology 152:58\u201366. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.004","journal-title":"Neuropharmacology"},{"key":"4320_CR69","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11064-011-0594-z","volume":"37","author":"D Alonso-Alconada","year":"2012","unstructured":"Alonso-Alconada D, \u00c1lvarez A, \u00c1lvarez FJ, Mart\u00ednez-Orgado JA, Hilario E (2012) The cannabinoid WIN 55212\u20132 mitigates apoptosis and mitochondrial dysfunction after hypoxia ischemia. Neurochem Res 37:161\u2013170. https:\/\/doi.org\/10.1007\/s11064-011-0594-z","journal-title":"Neurochem Res"},{"key":"4320_CR70","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms21041283","volume":"21","author":"D Alonso-Alconada","year":"2020","unstructured":"Alonso-Alconada D, \u00c1lvarez FJ, Go\u00f1i-De-cerio F, Hilario E, \u00c1lvarez A (2020) Cannabinoid-mediated modulation of oxidative stress and early inflammatory response after hypoxia\u2013ischemia. Int J Mol Sci 21:1283. https:\/\/doi.org\/10.3390\/ijms21041283","journal-title":"Int J Mol Sci"},{"key":"4320_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.595635","volume":"11","author":"F Patricio","year":"2020","unstructured":"Patricio F, Morales-Andrade AA, Patricio-Mart\u00ednez A, Lim\u00f3n ID (2020) Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson\u2019s disease. Front Pharmacol 11:595635. https:\/\/doi.org\/10.3389\/fphar.2020.595635","journal-title":"Front Pharmacol"},{"key":"4320_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.11.020","volume":"146","author":"L Barata","year":"2019","unstructured":"Barata L, Arruza L, Rodr\u00edguez MJ et al (2019) Neuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage. Neuropharmacology 146:1\u201311. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.11.020","journal-title":"Neuropharmacology"},{"key":"4320_CR73","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fnins.2016.00323","volume":"10","author":"H Lafuente","year":"2016","unstructured":"Lafuente H, Pazos MR, Alvarez A, Mohammed N, Santos M, Arizti M, Alvarez FJ, Martinez-Orgado JA (2016) Effects of cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-ischemia. Front Neurosci 10:323. https:\/\/doi.org\/10.3389\/fnins.2016.00323","journal-title":"Front Neurosci"},{"key":"4320_CR74","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/pr.2016.149","volume":"80","author":"HT Garberg","year":"2016","unstructured":"Garberg HT, Huun MU, Escobar J, Martinez-Orgado J, L\u00f8berg E-M, Solberg R, Saugstad OD (2016) Short-term effects of cannabidiol after global hypoxia-ischemia in newborn piglets. Pediatr Res 80:710\u2013718. https:\/\/doi.org\/10.1038\/pr.2016.149","journal-title":"Pediatr Res"},{"key":"4320_CR75","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.brainres.2010.09.050","volume":"1362","author":"D Alonso-Alconada","year":"2010","unstructured":"Alonso-Alconada D, Alvarez FJ, Alvarez A, Mielgo VE, Go\u00f1i-De-Cerio F, Rey-Santano MC, Caballero A, Martinez-Orgado J, Hilario E (2010) The cannabinoid receptor agonist WIN 55,212\u20132 reduces the initial cerebral damage after hypoxic-ischemic injury in fetal lambs. Brain Res 1362:150\u2013159. https:\/\/doi.org\/10.1016\/j.brainres.2010.09.050","journal-title":"Brain Res"},{"key":"4320_CR76","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1871527315666160927110305","volume":"16","author":"N Mohammed","year":"2016","unstructured":"Mohammed N, Ceprian M, Jimenez L, Pazos M, Mart\u00ednez-Orgado J (2016) Neuroprotective effects of cannabidiol in hypoxic ischemic insult. The therapeutic window in newborn mice. CNS Neurol Disord Drug Targets 16:102\u2013108. https:\/\/doi.org\/10.2174\/1871527315666160927110305","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"4320_CR77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/0091270002238789","volume":"42","author":"R Mechoulam","year":"2002","unstructured":"Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11\u201319. https:\/\/doi.org\/10.1177\/0091270002238789","journal-title":"J Clin Pharmacol"},{"key":"4320_CR78","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"SA Millar","year":"2018","unstructured":"Millar SA, Stone NL, Yates AS, O\u2019Sullivan SE (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 9:1365. https:\/\/doi.org\/10.3389\/fphar.2018.01365","journal-title":"Front Pharmacol"},{"key":"4320_CR79","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/bms.1200130206","volume":"13","author":"A Ohlsson","year":"1986","unstructured":"Ohlsson A, Lindgren J-E, Andersson S, Agurell S, Gillespie H, Hollister LE (1986) Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 13:77\u201383. https:\/\/doi.org\/10.1002\/bms.1200130206","journal-title":"Biomed Environ Mass Spectrom"},{"key":"4320_CR80","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA et al (2018) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391:1085\u20131096. https:\/\/doi.org\/10.1016\/S0140-6736(18)30136-3","journal-title":"Lancet"},{"key":"4320_CR81","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/epi.14628","volume":"60","author":"O Devinsky","year":"2019","unstructured":"Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C (2019) Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia 60:294\u2013302. https:\/\/doi.org\/10.1111\/epi.14628","journal-title":"Epilepsia"},{"key":"4320_CR82","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fendo.2018.00584","volume":"9","author":"S Paternoster","year":"2018","unstructured":"Paternoster S, Falasca M (2018) Dissecting the physiology and pathophysiology of glucagon-like peptide-1. Front Endocrinol 9:584. https:\/\/doi.org\/10.3389\/fendo.2018.00584","journal-title":"Front Endocrinol"},{"key":"4320_CR83","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.physbeh.2016.03.016","volume":"159","author":"XT Jia","year":"2016","unstructured":"Jia XT, Ye-Tian Y-L et al (2016) Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-\u03b2 peptide-induced impairment of spatial learning and memory in rats. Physiol Behav 159:72\u201379. https:\/\/doi.org\/10.1016\/j.physbeh.2016.03.016","journal-title":"Physiol Behav"},{"key":"4320_CR84","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jalz.2013.12.005","volume":"10","author":"T Foltynie","year":"2014","unstructured":"Foltynie T, Aviles-Olmos I (2014) Exenatide as a potential treatment for patients with Parkinson\u2019s disease: first steps into the clinic. Alzheimers Dement 10:S38\u2013S46. https:\/\/doi.org\/10.1016\/j.jalz.2013.12.005","journal-title":"Alzheimers Dement"},{"key":"4320_CR85","doi-asserted-by":"publisher","unstructured":"Eakin K, Li Y, Chiang Y-H, Hoffer BJ, Rosenheim H, Greig NH, Miller JP (2013) Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One 8:82016. https:\/\/doi.org\/10.1371\/journal.pone.0082016","DOI":"10.1371\/journal.pone.0082016"},{"key":"4320_CR86","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1038\/s41598-017-03792-9","volume":"7","author":"L Rachmany","year":"2017","unstructured":"Rachmany L, Tweedie D, Rubovitch V et al (2017) Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration. Sci Rep 7:3735. https:\/\/doi.org\/10.1038\/s41598-017-03792-9","journal-title":"Sci Rep"},{"key":"4320_CR87","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/bcpt.12974","volume":"122","author":"IR Marlet","year":"2018","unstructured":"Marlet IR, \u00d6lmestig JNE, Vilsb\u00f8ll T, Rungby J, Kruuse C (2018) Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischaemic stroke: a systematic review based on pre-clinical studies. Basic Clin Pharmacol Toxicol 122:559\u2013569. https:\/\/doi.org\/10.1111\/bcpt.12974","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4320_CR88","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/jcbfm.2011.51","volume":"31","author":"S Teramoto","year":"2011","unstructured":"Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, Hattori N, Urabe T (2011) Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 31:1696\u20131705. https:\/\/doi.org\/10.1038\/jcbfm.2011.51","journal-title":"J Cereb Blood Flow Metab"},{"key":"4320_CR89","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3389\/fncel.2019.00585","volume":"13","author":"S Zeng","year":"2020","unstructured":"Zeng S, Bai J, Jiang H et al (2020) Treatment with liraglutide exerts neuroprotection after hypoxic-ischemic brain injury in neonatal rats via the PI3K\/AKT\/GSK3\u03b2 pathway. Front Cell Neurosci 13:585. https:\/\/doi.org\/10.3389\/fncel.2019.00585","journal-title":"Front Cell Neurosci"},{"key":"4320_CR90","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.neuroscience.2012.09.025","volume":"226","author":"MD Wang","year":"2012","unstructured":"Wang MD, Huang Y, Zhang GP, Mao L, Xia YP, Mei YW, Hu B (2012) Exendin-4 improved rat cortical neuron survival under oxygen\/glucose deprivation through PKA pathway. Neuroscience 226:388\u2013396. https:\/\/doi.org\/10.1016\/j.neuroscience.2012.09.025","journal-title":"Neuroscience"},{"key":"4320_CR91","doi-asserted-by":"publisher","first-page":"26859","DOI":"10.1038\/srep26859","volume":"6","author":"H Zhu","year":"2016","unstructured":"Zhu H, Zhang Y, Shi Z, Lu D, Li T, Ding Y, Ruan Y, Xu A (2016) The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K\/AKT and MAPK pathways. Sci Rep 6:26859. https:\/\/doi.org\/10.1038\/srep26859","journal-title":"Sci Rep"},{"key":"4320_CR92","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1093\/brain\/awy220","volume":"141","author":"E Rocha-Ferreira","year":"2018","unstructured":"Rocha-Ferreira E, Poupon L, Zelco A, Leverin AL, Nair S, Jonsdotter A, Carlsson Y, Thornton C, Hagberg H, Rahim AA (2018) Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy. Brain 141:2925\u20132942. https:\/\/doi.org\/10.1093\/brain\/awy220","journal-title":"Brain"},{"key":"4320_CR93","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bcp.13135","volume":"83","author":"B Cirincione","year":"2017","unstructured":"Cirincione B, Mager DE (2017) Population pharmacokinetics of exenatide. Br J Clin Pharmacol 83:517\u2013526. https:\/\/doi.org\/10.1111\/bcp.13135","journal-title":"Br J Clin Pharmacol"},{"key":"4320_CR94","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/138920006776873490","volume":"7","author":"K Copley","year":"2006","unstructured":"Copley K, McCowen K, Hiles R, Nielsen L, Young A, Parkes D (2006) Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 7:367\u2013374. https:\/\/doi.org\/10.2174\/138920006776873490","journal-title":"Curr Drug Metab"},{"key":"4320_CR95","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1210\/jc.2019-00087","volume":"104","author":"LA van Meijel","year":"2019","unstructured":"van Meijel LA, Rooijackers HM, Tack CJ, de Galan BE (2019) Effect of the GLP-1 receptor agonist exenatide on impaired awareness of hypoglycemia in type 1 diabetes: a randomized controlled trial. J Clin Endocrinol Metab 104:4143\u20134150. https:\/\/doi.org\/10.1210\/jc.2019-00087","journal-title":"J Clin Endocrinol Metab"},{"key":"4320_CR96","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.clinthera.2005.02.008","volume":"27","author":"F Calara","year":"2005","unstructured":"Calara F, Taylor K, Han J, Zabala E, Moo Carr E, Wintle M, Fineman M (2005) A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 27:210\u2013215. https:\/\/doi.org\/10.1016\/j.clinthera.2005.02.008","journal-title":"Clin Ther"},{"key":"4320_CR97","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/15563650.2012.752495","volume":"51","author":"L Krishnan","year":"2013","unstructured":"Krishnan L, Dhatariya K, Gerontitis D (2013) No clinical harm from a massive exenatide overdose-a short report. Clin Toxicol 51:61. https:\/\/doi.org\/10.3109\/15563650.2012.752495","journal-title":"Clin Toxicol"},{"key":"4320_CR98","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/15563650701517707","volume":"46","author":"V Cohen","year":"2009","unstructured":"Cohen V, Teperikidis E, Jellinek SP, Rose J (2009) Acute exenatide (Byetta\u00ae) poisoning was not associated with significant hypoglycemia. Clin Toxicol 46:346\u2013347. https:\/\/doi.org\/10.1080\/15563650701517707","journal-title":"Clin Toxicol"},{"key":"4320_CR99","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.2174\/1381612823666170918123307","volume":"23","author":"KV Annink","year":"2018","unstructured":"Annink KV, Franz AR, Derks JB, R\u00fcdiger M, van Bel F, Benders MJNL (2018) Allopurinol: old drug, new indication in neonates? Curr Pharm Des 23:5935\u20135942. https:\/\/doi.org\/10.2174\/1381612823666170918123307","journal-title":"Curr Pharm Des"},{"key":"4320_CR100","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1203\/00006450-199304000-00018","volume":"33","author":"C Palmer","year":"1993","unstructured":"Palmer C, Towfighi J, Roberts RL, Heitjan DF (1993) Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats. Pediatr Res 33:405\u2013411. https:\/\/doi.org\/10.1203\/00006450-199304000-00018","journal-title":"Pediatr Res"},{"key":"4320_CR101","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0304-3940(92)90726-N","volume":"144","author":"GD Williams","year":"1992","unstructured":"Williams GD, Palmer C, Heitjan DF, Smith MB (1992) Allopurinol preserves cerebral energy metabolism during perinatal hypoxia-ischemia: a 31P NMR study in unanesthetized immature rats. Neurosci Lett 144:103\u2013106. https:\/\/doi.org\/10.1016\/0304-3940(92)90726-N","journal-title":"Neurosci Lett"},{"key":"4320_CR102","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1203\/00006450-199004000-00003","volume":"27","author":"C Palmer","year":"1990","unstructured":"Palmer C, Vannucci RC, Towfighi J (1990) Reduction of perinatal hypoxic-ischemic brain damage with allopurinol. Pediatr Res 27:332\u2013336. https:\/\/doi.org\/10.1203\/00006450-199004000-00003","journal-title":"Pediatr Res"},{"key":"4320_CR103","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s00221-002-1182-x","volume":"147","author":"C Peeters-Scholte","year":"2002","unstructured":"Peeters-Scholte C, van den Tweel E, Ioroi T, Post I, Braun K, Veldhuis W, Nicolay K, Groenendaal F, van Bel F (2002) Pharmacological interventions in the newborn piglet in the first 24 h after hypoxia-ischemia: a hemodynamic and electrophysiological perspective. Exp Brain Res 147:200\u2013208. https:\/\/doi.org\/10.1007\/s00221-002-1182-x","journal-title":"Exp Brain Res"},{"key":"4320_CR104","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1203\/01.PDR.0000081297.53793.C6","volume":"54","author":"C Peeters-Scholte","year":"2003","unstructured":"Peeters-Scholte C, Braun K, Koster J et al (2003) Effects of allopurinol and deferoxamine on reperfusion injury of the brain in newborn piglets after neonatal hypoxia-ischemia. Pediatr Res 54:516\u2013522. https:\/\/doi.org\/10.1203\/01.PDR.0000081297.53793.C6","journal-title":"Pediatr Res"},{"key":"4320_CR105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0006-8993(97)01453-4","volume":"787","author":"PJ Marro","year":"1998","unstructured":"Marro PJ, Hoffman D, Schneiderman R, Mishra OP, Delivoria-Papadopoulos M (1998) Effect of allopurinol on NMDA receptor modification following recurrent asphyxia in newborn piglets. Brain Res 787:71\u201377. https:\/\/doi.org\/10.1016\/S0006-8993(97)01453-4","journal-title":"Brain Res"},{"key":"4320_CR106","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.brainres.2005.11.061","volume":"1073\u20131074","author":"PJ Marro","year":"2006","unstructured":"Marro PJ, Mishra OP, Delivoria-Papadopoulos M (2006) Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res 1073\u20131074:444\u2013450. https:\/\/doi.org\/10.1016\/j.brainres.2005.11.061","journal-title":"Brain Res"},{"key":"4320_CR107","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12887-019-1566-8","volume":"19","author":"CA Maiwald","year":"2019","unstructured":"Maiwald CA, Annink KV, R\u00fcdiger M et al (2019) Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III). BMC Pediatr 19:210. https:\/\/doi.org\/10.1186\/s12887-019-1566-8","journal-title":"BMC Pediatr"},{"key":"4320_CR108","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pediatrneurol.2006.08.005","volume":"36","author":"T Gunes","year":"2007","unstructured":"Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I (2007) Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns. Pediatr Neurol 36:17\u201324. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2006.08.005","journal-title":"Pediatr Neurol"},{"key":"4320_CR109","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01068-0","author":"WY Chu","year":"2021","unstructured":"Chu WY, Annink KV, Nijstad AL et al (2021) Pharmacokinetic\/pharmacodynamic modelling of allopurinol, its active metabolite oxypurinol, and biomarkers hypoxanthine, xanthine and uric acid in hypoxic-ischemic encephalopathy neonates. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-021-01068-0","journal-title":"Clin Pharmacokinet"},{"key":"4320_CR110","doi-asserted-by":"publisher","unstructured":"Chaudhari T, McGuire W (2012) Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathy. Cochrane Database Syst Rev 11:CD006817. https:\/\/doi.org\/10.1002\/14651858.cd006817.pub3","DOI":"10.1002\/14651858.cd006817.pub3"},{"key":"4320_CR111","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.3390\/ijms22063142","volume":"22","author":"I Serrenho","year":"2021","unstructured":"Serrenho I, Rosado M, Dinis A, Cardoso CM, Gr\u00e3os M, Manadas B, Baltazar G (2021) Stem cell therapy for neonatal hypoxic-ischemic encephalopathy: a systematic review of preclinical studies. Int J Mol Sci 22:3142\u20133171. https:\/\/doi.org\/10.3390\/ijms22063142","journal-title":"Int J Mol Sci"},{"key":"4320_CR112","doi-asserted-by":"publisher","unstructured":"Bruschettini M, Romantsik O, Moreira A, Ley D, Th\u00e9baud B (2020) Stem cell-based interventions for the prevention of morbidity and mortality following hypoxic-ischaemic encephalopathy in newborn infants. Cochrane Database Syst Rev 8:CD013202. https:\/\/doi.org\/10.1002\/14651858.CD013202.pub2","DOI":"10.1002\/14651858.CD013202.pub2"},{"key":"4320_CR113","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(15)00347-6","volume":"15","author":"D Azzopardi","year":"2016","unstructured":"Azzopardi D, Robertson NJ, Bainbridge A et al (2016) Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. Lancet Neurol 15:145\u2013153. https:\/\/doi.org\/10.1016\/S1474-4422(15)00347-6","journal-title":"Lancet Neurol"},{"key":"4320_CR114","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41390-019-0511-8","volume":"86","author":"I Lingam","year":"2019","unstructured":"Lingam I, Meehan C, Avdic-Belltheus A, Martinello K, Hristova M, Kaynezhad P, Bauer C, Tachtsidis I, Golay X, Robertson NJ (2019) Short-term effects of early initiation of magnesium infusion combined with cooling after hypoxia\u2013ischemia in term piglets. Pediatr Res 86:699\u2013708. https:\/\/doi.org\/10.1038\/s41390-019-0511-8","journal-title":"Pediatr Res"},{"key":"4320_CR115","doi-asserted-by":"publisher","DOI":"10.3791\/52454","volume":"16","author":"KJ Kyng","year":"2015","unstructured":"Kyng KJ, Skajaa T, Kerrn-Jespersen S, Andreassen CS, Bennedsgaard K, Henriksen TB (2015) A piglet model of neonatal hypoxic-ischemic encephalopathy. J Vis Exp 16:e52454. https:\/\/doi.org\/10.3791\/52454","journal-title":"J Vis Exp"},{"key":"4320_CR116","unstructured":"European Medicines Agency: EMA\/CHMP\/272866\/2013 (2017) Benzyl alcohol and benzoic acid group used as excipients. In: https:\/\/www.ema.europa.eu\/en\/documents\/report\/benzyl-alcohol-benzoic-acid-group-usedexcipients-report-published-support-questions-answers-benzyl\/chmp\/508188\/2013-t_en.pdf.www.ema.europa.eu\/contact"},{"key":"4320_CR117","doi-asserted-by":"publisher","unstructured":"Weber C, Kammerer D, Streit B, Licht AH (2015) Phenolic excipients of insulin formulations induce cell death, pro-inflammatory signaling and MCP-1 release. Toxicol Rep 2:194\u2013202. https:\/\/doi.org\/10.1016\/j.toxrep.2014.11.019","DOI":"10.1016\/j.toxrep.2014.11.019"},{"key":"4320_CR118","unstructured":"U.S. Department of Health and Human Services (2005) Guidance for Industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. In: https:\/\/www.fda.gov\/media\/72309\/download"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04320-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-021-04320-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04320-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T11:04:53Z","timestamp":1646391893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-021-04320-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4320"],"URL":"https:\/\/doi.org\/10.1007\/s00431-021-04320-8","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Yes, we consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}